CoChat
Sign Up
Cited by 59Transplantation: Methods and OutcomesInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and Treatments

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Outcome of lung transplantation in idiopathic pulmonary fibrosis with previous anti-fibrotic therapy

Leuschner, Gabriela, Stocker, Florian, Veit, Tobias, Kneidinger, Nikolaus, Winter, Hauke, Schramm, René, Weig, Thomas, Matthes, Sandhya, Ceelen, Felix, Arnold, Paola, Munker, Dieter, Klenner, Friederike, Hatz, Rudolf, Frankenberger, Marion, Behr, Jürgen, Neurohr, Claus·2018·The Journal of Heart and Lung Transplantation
DOI 10.1016/j.healun.2017.07.002
Open this paper in CoChat — free account

Abstract

Background Anti-fibrotic drugs may interfere with wound-healing after major surgery, theoretically preventing sufficient bronchial anastomosis formation after lung transplantation (LTx). The aim of this study was to assess the impact of previous treatment with pirfenidone and nintedanib on outcomes after LTx in patients with idiopathic pulmonary fibrosis (IPF). Methods All patients with IPF undergoing LTx at the University of Munich between January 2012 and November 2016 were retrospectively screened for previous use of anti-fibrotics. Post-transplant outcome and survival of patients with and without anti-fibrotic treatment were analyzed. Results A total of 62 patients with IPF were transplanted (lung allocation score [mean ± SD] 53.1 ± 16.1). Of these, 23 (37.1%) received pirfenidone and 7 (11.3%) received nintedanib before LTx; the remaining 32 (51.6%) did not receive any anti-fibrotic drug (control group). Patients receiving anti-fibrotics were significantly older (p = 0.004) and their carbon monoxide diffusion capacity was significantly higher (p = 0.008) than in controls. Previous anti-fibrotic treatment did not increase blood product utilization, wound-healing or anastomotic complications after LTx. Post-transplant surgical revisions due to bleeding and/or impaired wound-healing were necessary in 18 (29.0%) patients (pirfenidone 30.4%, nintedanib 14.3%, control 31.3%; p = 0.66). Anastomosis insufficiency occurred in 2 (3.2%) patients, both in the control group. No patie…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.healun.2017.07.002

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 16

  1. Raghu, 2011, An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management, Am J Respir Crit Care Med, 183, 788, 10.1164/rccm.2009-040GL · DOI · Paper page
  2. Noble, 2011, Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials, Lancet, 377, 1760, 10.1016/S0140-6736(11)60405-4 · DOI · Paper page
  3. Karimi-Shah, 2015, Forced vital capacity in idiopathic pulmonary fibrosis—FDA review of pirfenidone and nintedanib, N Engl J Med, 372, 1189, 10.1056/NEJMp1500526 · DOI
  4. Hilberg, 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy, Cancer Res, 68, 4774, 10.1158/0008-5472.CAN-07-6307 · DOI · Paper page
  5. Ranpura, 2011, Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis, JAMA, 305, 487, 10.1001/jama.2011.51 · DOI
  6. Ley, 2012, A multidimensional index and staging system for idiopathic pulmonary fibrosis, Ann Intern Med, 156, 684, 10.7326/0003-4819-156-10-201205150-00004 · DOI · Paper page
  7. Egan, 2006, Development of the new lung allocation system in the United States, Am J Transplant, 6, 1212, 10.1111/j.1600-6143.2006.01276.x · DOI · Paper page
  8. Neurohr, 2010, Potential functional and survival benefit of double over single lung transplantation for selected patients with idiopathic pulmonary fibrosis, Transpl Int, 23, 887
  9. Neurohr, 2009, Tacrolimus and mycophenolate mofetil as first line immunosuppression after lung transplantation, Transpl Int, 22, 635, 10.1111/j.1432-2277.2009.00843.x · DOI
  10. Christie, 2005, Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant, 24, 1454, 10.1016/j.healun.2004.11.049 · DOI
  11. Stewart, 2007, Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection, J Heart Lung Transplant, 26, 1229, 10.1016/j.healun.2007.10.017 · DOI
  12. Estenne, 2002, Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria, J Heart Lung Transplant, 21, 297, 10.1016/S1053-2498(02)00398-4 · DOI
  13. Verleden, 2014, A new classification system for chronic lung allograft dysfunction, J Heart Lung Transplant, 33, 127, 10.1016/j.healun.2013.10.022 · DOI
  14. Delanote, 2016, Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series, BMC Pulm Med, 16, 156, 10.1186/s12890-016-0308-z · DOI · Paper page
  15. Egan, 2016, Effect of the lung allocation score on lung transplantation in the United States, J Heart Lung Transplant, 35, 433, 10.1016/j.healun.2016.01.010 · DOI
  16. Hayanga, 2015, Lung transplantation in patients with high lung allocation scores in the US: evidence for the need to evaluate score specific outcomes, J Transplant, 2015, 836751, 10.1155/2015/836751 · DOI

Cited by

Sorted by citations

Metadata

Authors
Leuschner, G., Stocker, F., Veit, T., Kneidinger, N., Winter, H., Schramm, R., Weig, T., Matthes, S., Ceelen, F., Arnold, P., Munker, D., Klenner, F., Hatz, R., Frankenberger, M., Behr, J., & Neurohr, C.
Affiliations
  • German Center for Lung Research (DE)
  • Ludwig-Maximilians-Universität München (DE)
  • Helmholtz Munich (DE)
Corresponding author
Leuschner, Gabriela
ORCID
Venue
The Journal of Heart and Lung Transplantation
Publisher
Elsevier BV
Published
2018-02
Volume
37
Issue
2
Pages
268-274
ISSN
1053-2498 (ISSN-L)
DOI
10.1016/j.healun.2017.07.002
OpenAlex
W2733752510
Cited by
59
References
6
Citations by year
2025: 4 · 2024: 1 · 2023: 10 · 2022: 4 · 2021: 11 · 2020: 6 · 2019: 12 · 2018: 11
FWCI
8.15
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • The Journal of Heart and Lung Transplantation (publishedVersion)
  • PubMed (publishedVersion)
  • Site cant be reached (submittedVersion)
  • PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Keywords
lung transplantation, idiopathic pulmonary fibrosis, antifibrotic therapy, pirfenidone, nintedanib, bronchial anastomosis, wound healing, anastomotic complications, post-transplant survival, surgical revision

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review